Key Points
- Bicara COO Ryan Cohlhepp sold 12,500 shares on April 15 at an average price of $23.01 for $287,625 under a pre‑arranged Rule 10b5‑1 plan, leaving him with 196,141 shares (a ~5.99% reduction), according to an SEC filing.
- The April sale continues a string of insider dispositions this year — Cohlhepp also sold shares on March 16 (12,500 at $19.66), March 3 (17,392 at $18.16) and Jan 22 (3,828 at $18.10).
- BCAX trades near its 12‑month high (~$24.25) with a ~$1.57B market cap; analysts show a consensus "Moderate Buy" with a $28 average price target (8 Buys, 3 Holds, 1 Sell) and the company recently posted a slight EPS beat.
Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) COO Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $23.01, for a total value of $287,625.00. Following the transaction, the chief operating officer directly owned 196,141 shares in the company, valued at approximately $4,513,204.41. This trade represents a 5.99% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ryan Cohlhepp also recently made the following trade(s):
- On Monday, March 16th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The stock was sold at an average price of $19.66, for a total transaction of $245,750.00.
- On Tuesday, March 3rd, Ryan Cohlhepp sold 17,392 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.16, for a total transaction of $315,838.72.
- On Thursday, January 22nd, Ryan Cohlhepp sold 3,828 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.10, for a total transaction of $69,286.80.
Bicara Therapeutics Stock Performance
Bicara Therapeutics stock opened at $24.01 on Friday. Bicara Therapeutics Inc. has a twelve month low of $7.80 and a twelve month high of $24.25. The firm has a market cap of $1.57 billion, a PE ratio of -9.49 and a beta of -1.23. The firm's 50 day moving average price is $18.65 and its two-hundred day moving average price is $17.57.
Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its quarterly earnings results on Monday, March 30th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.04. Equities analysts anticipate that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the business. Vestal Point Capital LP lifted its holdings in shares of Bicara Therapeutics by 2.0% during the third quarter. Vestal Point Capital LP now owns 5,100,000 shares of the company's stock worth $80,529,000 after buying an additional 100,000 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its position in shares of Bicara Therapeutics by 596.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company's stock valued at $54,472,000 after buying an additional 2,771,868 shares during the last quarter. Janus Henderson Group PLC bought a new stake in shares of Bicara Therapeutics in the fourth quarter valued at about $44,484,000. Vanguard Group Inc. lifted its stake in shares of Bicara Therapeutics by 9.8% in the third quarter. Vanguard Group Inc. now owns 2,200,925 shares of the company's stock valued at $34,753,000 after buying an additional 195,667 shares during the period. Finally, State Street Corp grew its position in Bicara Therapeutics by 179.5% during the fourth quarter. State Street Corp now owns 1,649,537 shares of the company's stock worth $27,762,000 after buying an additional 1,059,260 shares in the last quarter.
Analysts Set New Price Targets
BCAX has been the subject of several recent research reports. Wedbush reissued an "outperform" rating and issued a $30.00 price target on shares of Bicara Therapeutics in a research note on Tuesday, March 31st. Citigroup started coverage on shares of Bicara Therapeutics in a research note on Thursday, January 29th. They set an "outperform" rating on the stock. Citizens Jmp restated a "market outperform" rating and set a $31.00 price target on shares of Bicara Therapeutics in a report on Tuesday, March 31st. HC Wainwright lifted their price objective on shares of Bicara Therapeutics from $40.00 to $42.00 and gave the company a "buy" rating in a research note on Tuesday, March 31st. Finally, The Goldman Sachs Group upped their price objective on shares of Bicara Therapeutics from $14.00 to $16.00 and gave the stock a "neutral" rating in a report on Tuesday, March 31st. Eight research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $28.00.
Get Our Latest Stock Report on Bicara Therapeutics
Bicara Therapeutics Company Profile
(
Get Free Report)
Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company's research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.
The company's lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
